10664601 - GAU: 1627

Approved for use through 10/31/99, OMB 0651-0031
Patent and Trademark Office: U.S./DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to a collection of information unless it contains a valid OMB control number Complete if Known Substitute for form 1449A/PTO 10/664,601 Application Number INFORMATION DISCLOSURE Filing Date 09/18/2003 First Named Inventor Weenna Bucay-Couto STATEMENT BY APPLICANT Group Art Unit (use as many sheets as necessary) Thurman K. Page **Examiner Name** of 1 Attorney Docket Number 03-278US1

FR	miner	Cite	U.S. Patent	Document	Name of Patentee or Applicant	Date of Publication of Cited Document	
Thiti	ials*	No.	Number Class/Subclass		of Cited Document	MM-DD-YYYY	
-	_	-	0.105.101.51	1011100			
	TR/	1	6,495,164 B1	424/489	Ramstack et al.	12-17-2002	
	T.B./	2	4,927,806 A	514/2	Kramer et al.	05-22-1990	

Examiner Initials*	Cite No.	U.S. Patent Ap	plications	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	
	1	Number	Class/Subclass			
/T.B.	/1	2003/064998 A1	514/259.41	Francois et al.	04-03-2003	

Examiner	Cite	Foreign Patent Document			Name of Patentee or Applicant of	Date of Publication of	T
Initials*	No. 1	Office ³ Number ⁴		Class/Subclass	Cited Document	Cited Document MM-DD-YYYY	
/T.B./	1	EP	1 197 208 A1	A61K 9/52	Takeda Chemical Industries Ltd	04-17-2002	
111	2	EP	1 078 636 A1	A61K 31/715	Zhao	02-28-2001	
V	3	GB	811,717	A61k	Pfizer & Co., Inc.	04-08-1959	

Examiner Signature	/Timothy Betton/	Date Considered	09/30/2010				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not							

considered. Include copy of this form with next communication to applicant.

12Unique citation designation number. 2Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and trademark Office, Washington, DC 20231.